C12Y 204/01165
N-acetylneuraminylgalactosylglucosylceramide beta-1,4-n-acetylgalactosaminyltransferase
Official title: N-Acetylneuraminylgalactosylglucosylceramide beta-1,4-N-acetylgalactosaminyltransferase (2.4.1.165)
C12Y204/01165 (N-acetylneuraminylgalactosylglucosylceramide beta-1,4-n-acetylgalactosaminyltransferase) appears on 3 US grants and 6 published applications in this corpus.
Search patents in C12Y- Granted patents
- 3
- Published applications
- 6
- Assignees
- 4
- Inventors
- 6
- Latest grant
- 28 Jan 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 2 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
| 2025 | 1 | 1 |
By publication year.
Recent patents
- Identification of porcine xenoantigens28 Jan 2025US 12,207,629 B2Indiana University Research and Technology Corporation
- Methods and materials for GALGT2 gene therapy22 Oct 2024US 12,121,595 B2Research Institute At Nationwide Children's Hospital
- Methods and materials for GALGT2 gene therapy20 Apr 2021US 10,980,897 B2Research Institute At Nationwide Children's Hospital
- Methods and materials for galgt2 gene therapy23 Jan 2025US 2025/0025578 A1Research Institute At Nationwide Children's Hospital
- Identification of Porcine Xenoantigens16 Jun 2022US 2022/0183262 A1Indiana University Research and Technology Corporation
- Blood product derived from gene knockout pig and use thereof19 Aug 2021US 2021/0254004 A1Gcreatene (Suzhou) Biotechnology Co., Ltd.
- Methods and Materials for GALGT2 Gene Therapy22 Jul 2021US 2021/0220484 A1Research Institute At Nationwide Childeren's Hospital
- Identification of porcine xenoantigens1 Aug 2019US 2019/0230907 A1Indiana University Research and Technology Corporation
Most cited
By later US patents